Earlier this year, the World Health Organization called for a “concerted effort” to drive down the cost of new hepatitis C drugs. Gilead Sciences is answering that call with this new announcement; Seven India-based drug makers have been licensed to sell cheaper versions of sofosbuvir to 91 developing nations. More information on this licensing agreement here. (Source: Evolve Beyond The Page, 9/15/14).
You are here: / / How Is Gilead Making Sovaldi More Affordable For Developing Nations?